AstraZeneca PLC
1454.00
23-December-24 11:29:54
15 minutes delayed
Stocks
+21.00
+1.47%
Today's range
1439.00 - 1458.00
ISIN
N/A
Source
NASD.OMX SE
-
NetDania - New 12 months High: AstraZeneca PLC
22 Jul 2024 08:17:57 By NetDania Notify
-
Interesting AZN Put And Call Options For August 23rd
03 Jul 2024 13:16:51 By NASDAQ US Markets
-
AstraZeneca: CHMP Recommends Lynparza And Imfinzi Combination For EU Approval In Endometrial Cancer
01 Jul 2024 03:09:21 By NASDAQ US Markets
-
Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
28 Jun 2024 10:33:02 By NASDAQ Stocks
-
AstraZeneca: Imfinzi Trial Fails To Meet Endpoint In Early-stage Non-small Cell Lung Cancer
25 Jun 2024 03:08:02 By NASDAQ US Markets
-
AstraZeneca: Phase III Truqap Trial Plus Chemotherapy Fails To Meet Primary Goals In Breast Cancer
18 Jun 2024 03:15:21 By NASDAQ US Markets
-
AstraZeneca's Calquence Combo Cuts Progression Risk By 27% In Mantle Cell Lymphoma Trial
16 Jun 2024 12:33:03 By NASDAQ US Markets
-
FDA Approves AstraZeneca's Farxiga For Pediatric Use In Type-2 Diabetes
12 Jun 2024 21:53:19 By NASDAQ US Markets
-
NetDania - New 12 months High: AstraZeneca PLC
10 Jun 2024 03:21:31 By NetDania Notify
-
1 Biopharma Stock Setting the New Standard in Cancer Care Drugs
07 Jun 2024 12:13:02 By NASDAQ Stocks
-
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference
05 Jun 2024 19:29:29 By Forbes - World
-
AstraZeneca Completes Acquisition Of Fusion Pharma
05 Jun 2024 03:08:45 By NASDAQ US Markets
-
CHMP Recommends Approval Of AstraZeneca's Tagrisso Combo For EGFR-Mutated Advanced Lung Cancer
03 Jun 2024 03:15:45 By NASDAQ US Markets
-
Amgen's Bkemv Approved As First Interchangeable Biosimilar To Soliris
30 May 2024 05:59:20 By NASDAQ US Markets
-
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
29 May 2024 10:20:48 By NASDAQ US Markets
-
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
29 May 2024 08:32:19 By NASDAQ US Markets
-
AZN:Datopotamab Deruxtecan Shows Favorable Survival Results, Falls Short Of Statistical Significance
27 May 2024 02:59:14 By NASDAQ US Markets
-
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
24 May 2024 10:30:58 By NASDAQ Stocks
-
NetDania - New 12 months High: AstraZeneca PLC
23 May 2024 10:35:27 By NetDania Notify
-
AstraZeneca Targets $80 Bln Revenue By 2030, Plans To Launch 20 New Medicines
21 May 2024 03:02:29 By NASDAQ US Markets